BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 10561277)

  • 21. Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: a phase I-II study.
    Brade A; Brierley J; Oza A; Gallinger S; Cummings B; Maclean M; Pond GR; Hedley D; Wong S; Townsley C; Brezden-Masley C; Moore M
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1027-36. PubMed ID: 17197132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine.
    Kornek GV; Pötter R; Selzer E; Schratter A; Ulrich-Pur H; Rogy M; Kraus G; Scheithauer W
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):665-71. PubMed ID: 11172947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study.
    Van Laethem JL; Demols A; Gay F; Closon MT; Collette M; Polus M; Houbiers G; Gastelblum P; Gelin M; Houtte PV; Closset J
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):974-80. PubMed ID: 12829132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial.
    Small W; Berlin J; Freedman GM; Lawrence T; Talamonti MS; Mulcahy MF; Chakravarthy AB; Konski AA; Zalupski MM; Philip PA; Kinsella TJ; Merchant NB; Hoffman JP; Benson AB; Nicol S; Xu RM; Gill JF; McGinn CJ
    J Clin Oncol; 2008 Feb; 26(6):942-7. PubMed ID: 18281668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concurrent infusional gemcitabine and radiation in the treatment of advanced unresectable GI malignancy: a phase I study.
    Mohiuddin M; Kudrimoti M; Regine WF; McGrath PC; Hanna N; John W
    Cancer J; 2002; 8(3):255-62. PubMed ID: 12074325
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer.
    Hidalgo M; Castellano D; Paz-Ares L; Gravalos C; Diaz-Puente M; Hitt R; Alonso S; Cortes-Funes H
    J Clin Oncol; 1999 Feb; 17(2):585-92. PubMed ID: 10080603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial.
    Kent E; Sandler H; Montie J; Lee C; Herman J; Esper P; Fardig J; Smith DC
    J Clin Oncol; 2004 Jul; 22(13):2540-5. PubMed ID: 15226322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
    Schilsky RL; Bertucci D; Vogelzang NJ; Kindler HL; Ratain MJ
    J Clin Oncol; 2002 Jan; 20(2):582-7. PubMed ID: 11786589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II trial of primary radiation therapy and concurrent chemotherapy for patients with locally advanced pancreatic cancer.
    Magnino A; Gatti M; Massucco P; Sperti E; Faggiuolo R; Regge D; Capussotti L; Gabriele P; Aglietta M
    Oncology; 2005; 68(4-6):493-9. PubMed ID: 16020980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study.
    Blackstock AW; Mornex F; Partensky C; Descos L; Case LD; Melin SA; Levine EA; Mishra G; Limentani SA; Kachnic LA; Tepper JE
    Br J Cancer; 2006 Aug; 95(3):260-5. PubMed ID: 16868545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-Based Chemoradiation in Locally Advanced Pancreatic Cancer.
    van Zweeden AA; van der Vliet HJ; Wilmink JW; Meijerink MR; Meijer OW; Bruynzeel AM; van Tienhoven G; Giovannetti E; Kazemier G; Jacobs MA; Verheul HM
    Clin Cancer Res; 2015 Oct; 21(20):4569-75. PubMed ID: 26056353
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I study of gemcitabine plus palliative radiation therapy for advanced lung cancer.
    Choi B; Robins HI; Schiller J; Mehta M
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):175-9. PubMed ID: 18305938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
    Tsavaris N; Kosmas C; Skopelitis H; Gouveris P; Kopterides P; Loukeris D; Sigala F; Zorbala-Sypsa A; Felekouras E; Papalambros E
    Invest New Drugs; 2005 Aug; 23(4):369-75. PubMed ID: 16012797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer.
    Sudo K; Yamaguchi T; Ishihara T; Nakamura K; Hara T; Denda T; Tawada K; Imagumbai T; Araki H; Sakai M; Hatano K; Kawakami H; Uno T; Ito H; Yokosuka O
    Int J Radiat Oncol Biol Phys; 2011 May; 80(1):119-25. PubMed ID: 20605363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
    Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II trial of a 24-hour infusion of gemcitabine in previously untreated patients with advanced pancreatic adenocarcinoma.
    Eckel F; Schmelz R; Erdmann J; Mayr M; Lersch C
    Cancer Invest; 2003; 21(5):690-4. PubMed ID: 14628426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unresectable pancreatic adenocarcinoma: a Grupo Español Multidisciplinario en Cáncer Digestivo (GEMCAD) study.
    Aparicio J; García-Mora C; Martín M; Petriz ML; Feliu J; Sánchez-Santos ME; Ayuso JR; Fuster D; Conill C; Maurel J
    PLoS One; 2014; 9(1):e82209. PubMed ID: 24416138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer.
    Sangar VK; McBain CA; Lyons J; Ramani VA; Logue JP; Wylie JP; Clarke NW; Cowan RA
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):420-5. PubMed ID: 15667962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I study of conformal radiotherapy and concurrent full-dose gemcitabine with erlotinib for unresected pancreatic cancer.
    Robertson JM; Margolis J; Jury RP; Balaraman S; Cotant MB; Ballouz S; Boxwala IG; Jaiyesimi IA; Nadeau L; Hardy-Carlson M; Marvin KS; Wallace M; Ye H
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e187-92. PubMed ID: 21549514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer.
    Epelbaum R; Rosenblatt E; Nasrallah S; Faraggi D; Gaitini D; Mizrahi S; Kuten A
    J Surg Oncol; 2002 Nov; 81(3):138-43. PubMed ID: 12407726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.